Journals / Kulak Burun Boğaz ve Baş Boyun Cerrahisi / 2021 / Cilt: 29 - Sayı: 3

Neurotological Manifestations of Patients with COVID-19

COVID-19 Hastalarında Nöro-otolojik Semptomlar

Pages
168–175
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results were evaluated in three separate categoriesaccording to the presence or absence of neurotologic symptoms,according to gender and according to age as >60 years and

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the frequency, discomfort level,duration, and laboratory tests of neurotological symptoms (hearing loss,hyperacusis and vertigo) and their association with eustachian tube dysfunction(ETD), smell and taste impairment in hospitalized patientswith coronavirus disease-2019 (COVID-19).
📊
Key Findings & Data:Material and Methods:The study prospectively enrolled a consecutive series of patients withCOVID-19, who were hospitalized and followed up for the first 3months.
💡
Conclusion & Impact:The results were evaluated in three separate categoriesaccording to the presence or absence of neurotologic symptoms,according to gender and according to age as >60 years and
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate the frequency, discomfort level,duration, and laboratory tests of neurotological symptoms (hearing loss,hyperacusis and vertigo) and their association with eustachian tube dysfunction(ETD), smell and taste impairment in hospitalized patientswith coronavirus disease-2019 (COVID-19). Material and Methods:The study prospectively enrolled a consecutive series of patients withCOVID-19, who were hospitalized and followed up for the first 3months. In addition to demographic data and laboratory test (the highestvalue for D-dimer, ferritin, C-reactive protein and neutrophil; thelowest value for fibrinogen, lymphocyte and platelet during hospitalization)results, a record was made of visual analogue scale scores ofsymptoms that present. The results were evaluated in three separate categoriesaccording to the presence or absence of neurotologic symptoms,according to gender and according to age as >60 years and

Özet

Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] enfeksiyonu geçiren ve hastanede yatışı gerçekleştirilen hastalarda nöro-otolojik semptomların (işitme kaybı, hiperakuzi, baş dönmesi) sıklığı, rahatsızlık düzeyi, semptom süreleri ve laboratuvar sonuçlarının araştırılması ve bunların östaki tüpü disfonksiyonu (ÖTD), koku ve tat kaybı ile birlikteliklerini değerlendirmek. Gereç ve Yöntemler: Çalışmaya, prospektif olarak hastaneye yatışı gerçekleşen COVID-19 enfeksiyonu geçiren hastalar dâhil edilmiştir ve hastaların ilk 3 aylık süreci takip edilmiştir. Demografik veriler ve laboratuvar test sonuçlarına (D-dimer, ferritin, C-reaktif protein ve nötrofil değerlerinin en yükseği; fibrinojen, lenfosit ve platelet değerlerinin en düşüğü) ek olarak, sorgulanan semptomlar hastada mevcut ise bunların vizüel analog skala skorları kayıt edildi. Sonuçlar, nöro-otolojik semptomların varlığına veya yokluğuna göre cinsiyete ve yaşa göre (>60 ve

🔖

Cite This Article

ERAVCI, F. C., KORKMAZ, C., YOSUNKAYA, Ş., DÜNDAR, M. A., ALAFİFİ, M., DEMİRBAŞ, S., VATANSEV, H., ARBAĞa, H. (2022). Neurotological Manifestations of Patients with COVID-19. Kulak Burun Boğaz ve Baş Boyun Cerrahisi, Cilt: 29 - Sayı: 3, 168–175. https://ajindex.com/articles/576605

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. World Health Organization [Internet]. © 2020 WHO [cited: 22.11.2020]. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update Available from: [Link] 2. Kandemirli SG, Altundag A, Yildirim D, Tekcan Sanli DE, Saatci O. Olfactory bulb MRI and paranasal sinus CT findings in persistent COVID-19 anosmia. Acad Radiol. 2021
  2. 28(1): 28-35. [Crossref] [PubMed] [PMC] 3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020
  3. 395(10224):565-74. [Crossref] [PubMed] [PMC] 4. Salahuddin H, Afreen E, Sheikh IS, Lateef S, Dawod G, Daboul J, et al. Neurological predictors of clinical outcomes in hospitalized patients with COVID-19. Front Neurol. 2020
  4. 585944. [Crossref] [PubMed] [PMC] 5. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020
  5. 77(6):683- 90. [Crossref] [PubMed] [PMC] 6. Mustafa MWM. Audiological profile of asymptomatic Covid-19 PCR-positive cases. Am J Otolaryngol. 2020
  6. 41(3):102483. [Crossref] [PubMed] [PMC] 7. Özçelik Korkmaz M, Eğilmez OK, Özçelik MA, Güven M. Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection. Eur Arch Otorhinolaryngol. 2020:1-11. [Crossref] [PubMed] [PMC] 8. Karimi-Galougahi M, Naeini AS, Raad N, Mikaniki N, Ghorbani J. Vertigo and hearing loss during the COVID-19 pandemic-is there an association? Acta Otorhinolaryngol Ital. 2020
  7. 40(6):463-5. [Crossref] [PubMed] [PMC] 9. Kilic O, Kalcioglu MT, Cag Y, Tuysuz O, Pektas E, Caskurlu H, et al. Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS- COV-2 in the etiology of sudden sensorineural hearing loss. Int J Infect Dis. 2020
  8. [Crossref] [PubMed] [PMC] 10. Almufarrij I, Uus K, Munro KJ. Does coronavirus affect the audio-vestibular system? A rapid systematic review. Int J Audiol. 2020
  9. 59(7):487-91. [Crossref] [PubMed] 11. Altin F, Cingi C, Uzun T, Bal C. Olfactory and gustatory abnormalities in COVID-19 cases. Eur Arch Otorhinolaryngol. 2020
  10. 277(10): 2775-81. [Crossref] [PubMed] [PMC] 12. Butowt R, Bilinska K. SARS-CoV-2: Olfaction, brain ınfection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020
  11. 11(9):1200- 3. [Crossref] [PubMed] [PMC] 13. Uranaka T, Kashio A, Ueha